The tumor suppressor gene p53 and its family members p63/p73 are critical determinants of tumorigenesis. ΔNp63 is a splice variant of p63, which lacks the Nterminal transactivation domain. It is thought to antagonize p53-, p63-and p73-dependent translation, thus blocking their tumor suppressor activity. In our studies of the pediatric solid tumors neuroblastoma and osteosarcoma, we find overexpression of ΔNp63; however, there is no correlation of ΔNp63 expression with p53 mutation status.
INTRODUCTION
p63 exhibits high sequence and structural homology to the tumor suppressor protein p53 (Trp53), and to another member of this family, p73 (Trp73) (1, 2) . Studies using genetically engineered mice have elucidated a central role for p63 in skin development and the aging of epithelial tissues (3) (4) (5) (6) (7) . Through the use of alternative promoters, the p63 gene generates transcripts encoding two major classes of protein isoforms: TAp63 and ΔNp63. TAp63 contains an N-terminal transactivation (TA) domain, whereas ΔNp63 lacks this domain (2) . Additional diversity arises through alternative splicing, which generates proteins with unique C-termini, designated α, β and γ. Together, these give rise to six unique p63 transcripts. All of these maintain a DNA-binding domain with significant homology to p53, but with somewhat altered target specificity (8, 9) .
Several reports both from in vitro and in vivo experiments have suggested that the
TAp63 isoforms act as tumor suppressor genes. For instance, TAp63 isoforms suppress metastasis through induction of senescence (10) and transcriptional activation of Dicer1 and mir-130b (11) . TAp63 −/− mice develop metastatic mammary and lung adenocarcinoma, as well as squamous cell carcinoma with metastases to the lung, liver and brain (11) .
The roles of the ΔNp63 isoforms seem to be more complex. Early studies showed that the ΔNp63 isoforms oppose p53-, TAp63-and TAp73-mediated transcription (and therefore apoptosis and cell cycle arrest), suggesting an oncogenic role for ΔNp63 isoforms (2, 9, (12) (13) (14) . Other studies have demonstrated effects that are independent of any dominant negative inhibitory activity, such as targeting of the chromatin remodeler Lsh by ΔNp63, which results in stem cell proliferation and tumorigenesis (15) . Some reports show that ΔNp63 isoforms retain transcriptionally activity and can transactivate genes involved in epidermal morphogenesis (16, 17) and DNA repair (18) . ΔNp63 is overexpressed in some types of adult human cancer (19) , particularly squamous cell carcinoma (SCC) (20) , where it promotes oncogenesis by suppressing TAp73 (21) . In other tumor types, such as adenocarcinoma of the breast and prostate, ΔNp63 expression is lost during the tumorigenic process (22) . While mice which exhibit knocked down (17) or total loss of expression (23) Taken together, the role that p63 isoforms play in cancer merits further investigation.
Here, we show that two childhood malignancies, neuroblastoma and osteosarcoma, overexpress ΔNp63. We find in these tumors no correlation between p53 mutation and ΔNp63 overexpression. We hypothesize that ΔNp63 is a key modulator of tumorigenesis in these childhood cancers, independent of p53 status. We demonstrate that ΔNp63α exhibits gain of function activity, which leads to the expression of crucial angiogeneic factors and promotes tumor development. Finally, we show that there is a selection for cells expressing high levels of ΔNp63 in osteosarcoma metastasis. Together, these data suggest a central role for ΔNp63 in the progression and dissemination of these childhood cancers.
MATERIALS AND METHODS

Animal studies
All animal experiments were conducted in accordance with institutional animal care and use committee of the research Institute at Nationwide Children's Hospital. Approved protocols were designed to minimize the numbers of mice used and to minimize any flank of 6-week-old CB17SC scid -/-female mice (Taconic Farms, Germantown NY). All mice were maintained under barrier conditions. Tumor volumes were measured once per week as previously described (24) .
Cell culture
The neuroblastoma cell line SKNSH was maintained in RPMI supplemented with 10% FBS. SKNDZ was maintained in DMEM supplemented with 10% FBS plus 0. 
Immunoprecipitation and chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed according to the manufacturer's instructions (EZ ChIP™ Chromatin Immunoprecipitation Kit, Millipore).
Protein-DNA complexes were precipitated using a p63 antibody (4A4, Santa Cruz) and PCR was carried out using following specific primers: IL-6, forward: 5'-TAATAAGGTTTCCAATCAGCC-3' reverse: 5'-CTCCAGTCCTATATTTATTGG-3', IL-8 forward: 5'-CATCAGTTGCAAATCGTGGA-3', reverse: 5'-GTTTGTGCCTTATGGAG TGCT-3'
Immunoblot, immunohistochemistry (IHC) and cell cycle analysis
Cells were lysed on ice with lysis buffer (Cell Signaling Technology) supplemented with protease and phosphatase inhibitors (Thermoscientific), and 1mM PMSF (Sigma).
Immunoblots were probed with the following antibodies: Antibodies for the detection of β-Actin and p63 (4A4) were purchased from Santa Cruz. STAT3, pSTAT3 (Tyr-705), PARP, HIF-1α and VHL were detected using Cell Signaling Technology antibodies. Total proteins of control tissues were purchased from BioChain. Immunohistochemistry assay was performed as previously described (25 Quantitative migration, wound healing and endothelial cell tube formation assay.
Transwell migration assays were performed using previously published methods (25) . Migration was quantified using the ratio of the migrated cells over the total cells (migrated plus remaining cells) to determine the fraction of migrated cells in each individual experiment. Each experiment was performed in duplicate. Wound healing and endothelial cell tube formation assay were performed as previously described (25) .
RNA isolation, cDNA synthesis, and real time PCR (RT-PCR)
RNA isolation and reverse transcription were performed using the RNeasy Mini Kit (Qiagen) and Omniscript Reverse Transcriptase (Qiagen) according to the manufacturer's instructions. qPCR was performed on an ABI Prism 7900HD Sequence Detection System (Applied Biosystems) using the TaqMan Universal Mastermix (Applied Biosystems). TAp63 and ΔNp63 expression was quantified in real-time with a specific FAM-labeled MGB-probe (Applied Biosystems) and normalized to GAPDH (Applied Biosystems). Total RNA from control tissues used as a negative control in Real-time PCR assays were purchased from BioChain.
qRT-PCR analysis of FFPE primary osteosarcomas and lung metastases
Tissue from FFPE primary osteosarcomas and corresponding lung metastases was identified through our local pathology department after approval by our local Institutional Review Board. Eleven 5 micron sections were cut from each tumor and dried on glass slides. The central section was stained with H&E and scanned to a virtual slide. Nontumor portions of each unstained slide were scraped away using microdissecting blades.
The remaining tissue was then deparaffinized in xylene and fresh 100% ethanol x2, then scraped into a microcentrifuge tube. This was then processed using a Qiagen FFPE RNeasy kit according to the protocol recommended by the manufacturer. cDNA was 
Lentiviral production and siRNAs
The shRNA lentiviral constructs and high-titer lentiviral stocks were generated as 
RESULTS
Childhood neuroblastoma and osteosarcoma express high levels of ΔNp63α
To examine the expression of ΔNp63 in childhood cancers, we surveyed the solid tumor models available through the Pediatric Preclinical Testing Program (PPTP) (Supplementary Fig. S1 ). Using qRT-PCR with primers designed to distinguish TA from ΔN isoforms of p63, we found that the ΔNp63 isoform is highly expressed in more than 50% of neuroblastoma and osteosarcoma tumor xenografts, ranging in abundance from 3 to 4.5 log of expression in contrast to tissues of origin (Fig. 1A) . Interestingly, TA isoforms of p63 were not detectable by qRT-PCR in any of the analyzed samples. We also examined p63 protein expression in these xenografts. As shown in Fig. 1B , the expression of the ΔNp63 protein in these xenografts correlated with the expression of the ΔNp63 mRNA transcript (Fig. 1A) . In addition to xenografts, we also examined p63 protein expression in neuroblastoma and osteosarcoma cell lines. We found high-level ΔNp63α expression in more than 50% of the analyzed neuroblastoma cell lines and two analyzed osteosarcoma cell lines (Fig. 1C) . Consistent with prior studies showing ΔNp63α to be the major isoform (26, 27) , we detected p63 protein migration at 68 kDa, which is consistent with the mobility for the ΔNp63α isoform.
Oncogenic effects of ΔNp63α in neuroblastoma and osteosarcoma
ΔNp63α has been hypothesized to contribute to tumorigenesis based on its ability to inhibit p53-dependent transactivation (2, 28) . By this argument, overexpression of ΔNp63α might simply inactivate p53, abrogating the requirement for its loss during tumorigenesis. Were that hypothesis true, one would expect to find either ΔNp63 overexpression or p53 mutation, but not both. We found no consistent correlation between p53 mutation and ΔNp63α overexpression in neuroblastoma and osteosarcoma (Supplementary Table 1 ), which makes this hypothesis difficult to substantiate, at least in these tumors. We therefore hypothesized that ΔNp63α might endow cells with a gain of function, rather than simply blocking transcription of p53, TAp63 and TAp73.
To explore the precise function and biochemical mechanisms of ΔNp63α activity, we chose two representative cell lines from each tumor type that differ in their p53 status.
We sought to understand the biologic consequence of high-level ΔNp63α expression in neuroblastoma and osteosarcoma by using a Lentiviral-mediated shRNA approach. We designed and tested three constructs expressing ΔNp63-targeted short hairpin RNA (shRNA) in pLKO.1 vectors (Supplementary Fig. 2A ). None of these shRNA constructs inhibited expression of the TAp63 isoform ( Supplementary Fig. 2B ). Importantly, we were able to optimize lentiviral production and infection conditions in order to ensure essentially 100% infection of targeted cells, as assessed using viruses coexpressing the eGFP protein ( Supplementary Fig. 2C ). Under these conditions, we observed approximately 80% knockdown of endogenous ΔNp63α protein and mRNA in JHU-011 cells. These same constructs were used to infect two different neuroblastoma (SKNSH express wild-type p53 and SKNDZ express mutated p53) and osteosarcoma (OS-17 express wild-type p53 and OHS express mutated p53) cell lines ( Supplementary Fig.   2D ).
These transduced cell lines were used to study the effects of ΔNp63α expression on anchorage-independent growth and cell proliferation. As shown in Supplementary Fig.   3A -B, we found that inhibition of ΔNp63α significantly reduced both cell proliferation and colony formation in a soft agar assay. There was no difference in proliferation or colony formation that could be attributed to p53 status. The reduction in cell proliferation and colony formation following knockdown of endogenous ΔNp63α was not associated with apoptosis ( Supplementary Fig. 3C ).
We next investigated whether high ΔNp63α expression contributes to the tumorigenic phenotype in neuroblastoma and osteosarcoma. As shown in We assessed these tumors for expression of Ki-67, a well-described marker of proliferative activity. Depletion of endogenous ΔNp63α, significantly reduced Ki-67 reactivity in tumors (Fig. 3A-B) . Given the essential role that angiogenesis plays in tumor formation, we sought to evaluate angiogenic activity in these same tumors. Inhibition of endogenous ΔNp63α resulted in significant decrease of CD34 immunostaining, a wellestablished marker for tumor angiogenesis (Fig. 3A-B) . These data suggested that the contribution of ΔNp63 to progression in these tumors lies in a p53-independent, gain-offunction mechanism that involves both growth and angiogenic pathways.
ΔNp63α regulates VEGF activity and promotes migration
We sought to understand the mechanisms by which ΔNp63α modulates angiogenesis in neuroblastoma and osteosarcoma. One quick assessment of angiogenesis in vitro is the measurement of the ability of human umbilical vein endothelial cells (HUVEC) to form three-dimensional structures (tube formation). To test whether overexpression of ΔNp63α in HEK-293T could stimulate tube formation in endothelial cells, we examined endothelial tube formation using a transwell assay system, where soluble factors from HEK-293T cells stimulate endothelial tube formation (Fig. 4A) . We found that overexpression of ΔNp63α in HEK-293T cells resulted in stimulation of tubular structures in HUVEC cells (Fig. 4B-C) . Moreover, we found that overexpression of ΔNp63α increased wound-healing motility in HEK-293T and in primary normal human dermal fibroblast (NHDF) ( Supplementary Fig. 4A-B) . Depletion of the Fig. 4C ).
To determine whether the ΔNp63α isoform regulates VEGF secretion, we used ELISA to assess secreted VEGF levels in HEK-293T and NHDF cells transfected with either empty vector or a ΔNp63α expression construct. In contrast to control cells, ΔNp63α overexpressing cells secreted ~4-fold more VEGF in to the medium (Fig. 4D) .
Moreover, ΔNp63 knockdown markedly decreased VEGF secretion in SKNDZ and OS-17 cell lines (Fig. 4E) , suggesting a key role for ΔNp63α in VEGF secretion in these childhood tumors.
Given that p63 isoform are proteins with sequence-specific DNA-binding properties we hypothesized that ΔNp63α might alter the expression of genes critical to angiogenesis. Therefore, we examined VEGF expression in the presence of ΔNp63α in HEK-293T and NHDF cells. As shown in Figure 4F , expression of ΔNp63α increased luciferase activity in HEK-293T and NHDF cells that were co-transfected with a VEGF promoter-luciferase construct.
ΔNp63α induces STAT3 (Signal Transducer and Activator of Transcription 3) phosphorylation
NHDF and HEK-293T cells do not express detectable amounts of endogenous p63 or p73, and HEK-293T cells express SV40 large T antigen that inhibits endogenous p53.
Thus, transcriptional activation of the VEGF-Luc reporter by the ΔNp63α isoform was not likely due to any dominant negative effect on endogenous p53, p73 or p63. It is more probable that ΔN isoforms mediate a gain of function, which modulates cellular factor(s) that are important in the regulation of VEGF promoter activity.
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that regulates transcription of several genes associated with angiogenesis including VEGF (29, 30) . It has been shown that ΔNp63 promotes HIF-1 stabilization in the H1299 cell line by an unknown mechanism (31). Consistent with this report, we determined that overexpression of ΔNp63α isoforms induced HIF-1 stabilization in primary NHDF and HEK-293T cells under normoxic conditions (Fig. 5A) , leading to strong hypoxia response element (HRE) reporter activity (Fig. 5B) .
We then focused on the underlying mechanism of HIF-1 stabilization in our models. process might be occurring in our NHDF and HEK-293T cells, we probed cell lysates for activated STAT3. We found that only ΔNp63α-overexpressing cells showed increased STAT3 phosphorylation at Tyr-705 (Fig. 5D ). In addition, ΔNp63 knockdown in SKNDZ and OS-17 cell lines markedly decreased STAT3 phosphorylation at Tyr-705 (Fig. 5E ).
To show whether increased stability of HIF-1, and in turn, up-regulation of VEGF secretion, by ΔNp63α is indeed dependent on STAT3, we analyzed the effects of 
ΔNp63α expression on STAT3
−/− mouse embryonic fibroblasts (MEFs). As shown in Figure 5F , ΔNp63α expression on STAT3 −/− MEFs did not result in a significant increase in VEGF secretion, where VEGF production was evident in the control MEFs. We also found that ΔNp63α-dependent cell migration and the induction of HIF-1 reporter were abrogated in the absence of STAT3 ( Supplementary Fig. 5A-C) . Taken together, our data provide direct evidence that STAT3 activation by ΔNp63 is necessary to enhance HIF-1 stability, and therefore to increase VEGF secretion.
Transcriptional activity of Interleukin (IL-6 and IL-8) promoters are regulated by ΔNp63α
We next investigated the underlying molecular mechanism of STAT3 activation by
ΔNp63 isoform. We compared the profiles of secreted cytokines in the presence or absence of ΔNp63α using a human cytokine antibody array. As shown in Figure 6A Fig.6 ), we performed immunoblot analysis for STAT3 phosphorylation (Tyr-705). As shown in Figure 6C , only combined inhibition of IL-6 and IL-8 by specific siRNAs significantly reduced STAT3 phosphorylation level, indicating that either IL-6 or IL-8 activity induced by ΔNp63α-is sufficient to keep STAT3 activated.
ΔNp63 expression is enhanced in osteosarcoma lung metastases
We suspected that ΔNp63 expression might endow these childhood tumors with greater metastatic potential. To address this question, we analyzed tissue samples taken from primary osteosarcoma tumors or lung metastases from patients with osteosarcoma for expression of ΔNp63 by qRT-PCR. We hypothesized that, if primary tumors contain cells that are heterogeneous for the expression of many different genes, then metastases themselves would show a selection for genes important to metastasis. As shown in Fig.6D , lung metastasis from patients with osteosarcoma reveal markedly increased expression of ΔNp63, IL-6, and IL-8 when compared to primary tumors from the same patients. To ensure that we were not observing global enrichment of inflammatory genes, we tested for expression of a related chemokine, RARRES3, but did not find enrichment. This result provides strong support for the hypothesis that IL-6 and IL-8 expression, driven by ΔNp63, plays a central role in the malignant progression of these childhood tumors. These clinical data provide first evidence that ΔNp63 expression may be a crucial factor to drive lung metastasis in osteosarcoma.
DISCUSSION
While the role of p63 in epithelial development has been well described, the mechanism by which p63 contributes to tumor pathogenesis has remained uncertain. have demonstrated the importance of these pathways in growth, motility, and angiogenesis within these tumors. We have also shown data from human samples suggesting a role for this process in metastasis. Importantly, we find that the mechanisms that drive these processes function independent of p53 status.
The upstream mechanisms that result in ΔNp63 overexpression remain to be elucidated. We suspect that gene amplification or polymorphisms within the internal promoter region of ΔNp63 might contribute. Indeed, polymorphisms within the internal promoter of the p53 gene have been shown to drive the overexpression of Δ133p53, an oncogenic isoform of that gene in other tumor types (35). We anticipate that future studies will delineate this process.
As tumor cells multiply, hypoxia develops. Tumor cells must drive angiogenesis in order to progress further. The ability to activate this angiogenic switch is considered a hallmark of malignancy. We have shown that ΔNp63 drives tumors to express VEGF.
The ability to promote angiogenesis is likely to be one mechanism that drives the selection for these cells among metastases. While we wish to emphasize the potential role of ΔNp63 expression in angiogenesis, we note that it is difficult to establish the degree to which in vivo tumor take was impaired by decreased cell proliferation compared to the inability to form new vessels. We did make efforts to address this caveat, and provide data in supplementary We also demonstrated that stabilization of HIF-1 protein by ΔNp63α was the necessary step driving VEGF production, which is dependent on STAT3 activation. We were interested to find that this process occurs independent of alterations in VHL protein levels. The precise mechanism, which links STAT3 to the stabilization of HIF-1α, remains to be elucidated. One area of future investigation may be to determine whether STAT3 directly binds to HIF-1α and recruits it to the human VEGF promoter.
We are intrigued by the finding that tumors excised from the lungs of patients with osteosarcoma show marked high-level expression of ΔNp63 expression relative to the primary lesions from the same patients. We hypothesize that ΔNp63 endows cells with greater metastatic efficiency, as would be suggested given the way that ΔNp63 drives the production of pro-inflammatory (IL-6, IL-8) and angiogenic (VEGF) factors. Such a phenomenon would explain the profound selection for ΔNp63-expressing cells that we observed in the lung metastases (Supplementary Fig. 8 ). While the observations we Taken together, we demonstrate that ΔNp63 promotes tumor growth in neuroblastoma and osteosarcoma by promoting chronic proliferation and later on tumor angiogenesis by increasing secretion of IL-6 and IL-8 leading to elevated phosphorylation of STAT-3. Moreover, we found that elevated phosphorylation of STAT-3 induced stabilization of HIF-1α protein leading to increased VEGF secretion, which might be the driving force for tumor invasion and metastasis in these childhood tumors.
Importantly, our clinical data provide the first evidence that analyzing of ΔNp63 expression in osteosarcoma patient with lung metastasis might be used as a prognostic factor. Furthermore, the understanding the underlying molecular mechanism of lung metastasis by high-level ΔNp63 expression will provide new therapeutic approaches targeting lung metastasis in osteosarcoma patients. 
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